ECSP055912A - Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas - Google Patents
Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetasInfo
- Publication number
- ECSP055912A ECSP055912A EC2005005912A ECSP055912A ECSP055912A EC SP055912 A ECSP055912 A EC SP055912A EC 2005005912 A EC2005005912 A EC 2005005912A EC SP055912 A ECSP055912 A EC SP055912A EC SP055912 A ECSP055912 A EC SP055912A
- Authority
- EC
- Ecuador
- Prior art keywords
- diffosphate
- aminocarbonil
- adenosine
- antagonists
- receptor
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 abstract 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Los compuestos de la fórmula (I), donde m, n, R1, R2, R3, R4 y R6 tienen los valores que se definen en la memoria descriptiva, son útiles como inhibidores del difosfato de adenosina plaquetario. También se describen composiciones farmacéuticas que contienen estos compuestos, los métodos para usar estos compuestos como agentes antitrombóticos y los procesos para sintetizar estos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43279202P | 2002-12-11 | 2002-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP055912A true ECSP055912A (es) | 2005-11-22 |
Family
ID=32507994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005005912A ECSP055912A (es) | 2002-12-11 | 2005-07-11 | Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7056923B2 (es) |
| EP (1) | EP1578423B1 (es) |
| JP (1) | JP4662777B2 (es) |
| KR (1) | KR20050085580A (es) |
| CN (1) | CN1747732A (es) |
| AP (1) | AP2005003363A0 (es) |
| AT (1) | ATE477800T1 (es) |
| AU (1) | AU2003297763A1 (es) |
| BR (1) | BR0317222A (es) |
| CA (1) | CA2507657C (es) |
| DE (1) | DE60333866D1 (es) |
| EA (1) | EA200500899A1 (es) |
| EC (1) | ECSP055912A (es) |
| ES (1) | ES2348942T3 (es) |
| MX (1) | MXPA05006302A (es) |
| NO (1) | NO20053335L (es) |
| NZ (1) | NZ540872A (es) |
| OA (1) | OA12970A (es) |
| PL (1) | PL377053A1 (es) |
| RS (1) | RS20050450A (es) |
| UA (1) | UA83648C2 (es) |
| WO (1) | WO2004052366A1 (es) |
| ZA (1) | ZA200505492B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| EP1685135B1 (en) * | 2003-10-21 | 2010-05-26 | Inspire Pharmaceuticals, Inc. | TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| CA2619706A1 (en) * | 2005-08-17 | 2007-02-22 | Schering Corporation | Novel high affinity quinoline-based kinase ligands |
| DE102006020385A1 (de) * | 2006-04-28 | 2007-10-31 | Dade Behring Marburg Gmbh | Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| WO2008128647A1 (en) | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| MY148901A (en) | 2007-06-18 | 2013-06-14 | Sanofi Aventis | Pyrrole derivatives as p2y12 antagonists |
| JP4729133B2 (ja) | 2007-11-29 | 2011-07-20 | アクテリオン ファーマシューティカルズ リミテッド | ホスホン酸誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用 |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| CA2756542C (en) * | 2009-04-08 | 2017-08-22 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
| CA2756654C (en) | 2009-04-22 | 2017-08-22 | Actelion Pharmaceuticals Ltd | Thiazole derivatives and their use as p2y12 receptor antagonists |
| CN102304108B (zh) * | 2011-06-28 | 2013-11-06 | 中国药科大学 | 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途 |
| CN104151235B (zh) * | 2014-08-07 | 2016-01-20 | 南阳师范学院 | 一种喹啉衍生物制备方法 |
| DK3515924T3 (da) | 2016-09-22 | 2022-03-21 | Idorsia Pharmaceuticals Ltd | Krystallinske former |
| SG11201908128YA (en) | 2017-03-15 | 2019-10-30 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
| CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
| CN112920181A (zh) * | 2021-01-29 | 2021-06-08 | 中国医科大学 | N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US60474A (en) * | 1866-12-18 | Pbtee chick | ||
| GB1334705A (en) | 1970-06-19 | 1973-10-24 | Ici Ltd | Pharmaceutical compositions containing kynurenic acid derivatives |
| US4258192A (en) * | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| KR920703558A (ko) | 1990-11-15 | 1992-12-18 | 원본미기재 | 메타-치환 페닐알라닌 유도체 |
| AU5878194A (en) * | 1993-02-10 | 1994-08-29 | Pentapharm Ag | Piperazides of substituted phenylalanine derivates as thrombin inhibitors |
| KR0173034B1 (ko) | 1995-04-28 | 1999-03-30 | 성재갑 | 선택적 트롬빈 억제제 |
| US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
-
2003
- 2003-12-09 EA EA200500899A patent/EA200500899A1/ru unknown
- 2003-12-09 AT AT03796831T patent/ATE477800T1/de not_active IP Right Cessation
- 2003-12-09 BR BR0317222-8A patent/BR0317222A/pt not_active IP Right Cessation
- 2003-12-09 EP EP03796831A patent/EP1578423B1/en not_active Expired - Lifetime
- 2003-12-09 US US10/731,815 patent/US7056923B2/en not_active Expired - Fee Related
- 2003-12-09 CA CA2507657A patent/CA2507657C/en not_active Expired - Fee Related
- 2003-12-09 AP AP2005003363A patent/AP2005003363A0/xx unknown
- 2003-12-09 KR KR1020057010688A patent/KR20050085580A/ko not_active Withdrawn
- 2003-12-09 AU AU2003297763A patent/AU2003297763A1/en not_active Abandoned
- 2003-12-09 JP JP2004558607A patent/JP4662777B2/ja not_active Expired - Fee Related
- 2003-12-09 ES ES03796831T patent/ES2348942T3/es not_active Expired - Lifetime
- 2003-12-09 PL PL377053A patent/PL377053A1/pl not_active Application Discontinuation
- 2003-12-09 OA OA1200500175A patent/OA12970A/en unknown
- 2003-12-09 RS YUP-2005/0450A patent/RS20050450A/sr unknown
- 2003-12-09 WO PCT/US2003/039079 patent/WO2004052366A1/en not_active Ceased
- 2003-12-09 DE DE60333866T patent/DE60333866D1/de not_active Expired - Lifetime
- 2003-12-09 NZ NZ540872A patent/NZ540872A/en unknown
- 2003-12-09 MX MXPA05006302A patent/MXPA05006302A/es active IP Right Grant
- 2003-12-09 CN CNA2003801096637A patent/CN1747732A/zh active Pending
- 2003-12-09 UA UAA200506729A patent/UA83648C2/ru unknown
-
2005
- 2005-07-08 NO NO20053335A patent/NO20053335L/no not_active Application Discontinuation
- 2005-07-11 EC EC2005005912A patent/ECSP055912A/es unknown
-
2006
- 2006-01-12 US US11/331,621 patent/US7084142B2/en not_active Expired - Fee Related
- 2006-01-17 ZA ZA200505492A patent/ZA200505492B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL377053A1 (pl) | 2006-01-23 |
| ATE477800T1 (de) | 2010-09-15 |
| RS20050450A (sr) | 2007-08-03 |
| ES2348942T3 (es) | 2010-12-17 |
| WO2004052366A1 (en) | 2004-06-24 |
| BR0317222A (pt) | 2005-11-01 |
| NO20053335L (no) | 2005-09-07 |
| JP4662777B2 (ja) | 2011-03-30 |
| AU2003297763A1 (en) | 2004-06-30 |
| NO20053335D0 (no) | 2005-07-08 |
| DE60333866D1 (de) | 2010-09-30 |
| CA2507657C (en) | 2011-05-31 |
| EP1578423A1 (en) | 2005-09-28 |
| US7056923B2 (en) | 2006-06-06 |
| US20060122188A1 (en) | 2006-06-08 |
| NZ540872A (en) | 2007-08-31 |
| US7084142B2 (en) | 2006-08-01 |
| ZA200505492B (en) | 2006-03-29 |
| CA2507657A1 (en) | 2004-06-24 |
| CN1747732A (zh) | 2006-03-15 |
| US20040138229A1 (en) | 2004-07-15 |
| OA12970A (en) | 2006-10-13 |
| EA200500899A1 (ru) | 2006-02-24 |
| WO2004052366A9 (en) | 2005-06-23 |
| KR20050085580A (ko) | 2005-08-29 |
| JP2006511519A (ja) | 2006-04-06 |
| EP1578423B1 (en) | 2010-08-18 |
| UA83648C2 (ru) | 2008-08-11 |
| AP2005003363A0 (en) | 2005-09-30 |
| MXPA05006302A (es) | 2005-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP055912A (es) | Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas | |
| UY28572A1 (es) | Compuestos novedosos | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| ECSP067025A (es) | DERIVADOS DE TETRAAZABENZO [e] AZULENO Y SUS ANÁLOGOS | |
| ECSP077335A (es) | Inhibidores de la interaccion entre mdm2 y p53 | |
| EA200700189A1 (ru) | Производные хиназолина в качестве ингибиторов parp | |
| ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
| BRPI0410025A (pt) | derivados de amino-propanol como modulador do receptor de esfingosina-1-fosfato | |
| ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
| UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
| SV2008001369A (es) | Benzimidazoles | |
| ATE365740T1 (de) | Substituierte pyrazolopyrimidine | |
| IL181271A0 (en) | Triazolophthalazine derivatives and pharmaceutical compositions containing the same | |
| ATE335748T1 (de) | Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| CY1109808T1 (el) | Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α | |
| DK1641803T3 (da) | Thienopyrimidinderivater som kaliumkanalinhibitorer | |
| CR10974A (es) | Inhibidores de carboxipeptidasa b plasmatica (divisional) | |
| NO20061845L (no) | Fenyl-piperazinderivater som modulatorer for muskarine reseptorer | |
| ECSP078062A (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| SV2004001555A (es) | Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos | |
| DE602004011204D1 (de) | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. | |
| SE0403085D0 (sv) | Novel componds | |
| SE0303090D0 (sv) | Novel compounds | |
| SE0403086D0 (sv) | Compounds |